Home    About NDEI   Site Map   FAQ   Contact Us   Feedback   
       Advanced Search    
Home
Slide Library
Literature Alerts
On Demand Activities
Case Studies
Newsletters
Live Events
Treatment Guidelines
Patient Education
Clinical Trials
Product Indications
Calendar Of Events
Glossary
Other Resources
CME Opportunities


Your Online Resource for Diabetes Treatment
Home > Literature Alerts > Association of lower plasma fetuin-a lev...
Printer-Friendly Format
Email this to a friend
Highlight Glossary

Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes

OBJECTIVE: Fetuin-A is an inhibitor of vascular calcification and a mediator of insulin resistance. This study evaluated the association of plasma fetuin-A and peripheral arterial disease (PAD). RESEARCH DESIGN AND METHODS: A total of 738 individuals with type 2 diabetes (mean age 58.7 years, 37.1% female) without known cardiovascular or kidney disease were included in this cross-sectional analysis. RESULTS: Subjects with PAD had a significantly lower fetuin-A (264.3 vs. 293.4 ng/dl, P<0.001). In multivariable analysis, a 1-SD decrease in fetuin-A increased the odds of PAD (odds ratio 1.6, P=0.02). Subgroup analysis revealed an increased odds even in subjects with glomerular filtration rate >80 (odds ratio 1.9, P=0.05) or high-sensitivity C-reactive protein <3 mg/dl (odds ratio 2.7, P=0.002). CONCLUSIONS: Lower circulating fetuin-A is associated with PAD in type 2 diabetes beyond traditional and novel cardiovascular risk factors. Our findings suggest a potentially unique role for fetuin-A deficiency as a biomarker of PAD in patients with type 2 diabetes.

PMID: 19910501 [PubMed - indexed for MEDLINE]


Eraso LH, Ginwala N, Qasim AN, et al. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care. 2010;33(2):408-410.
 

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.
Disclaimer Statement - Privacy Statement